IQVIA reported second-quarter 2026 earnings, with organic revenue growth accelerating to 6% year-over-year — triple the prior year's rate. The company also raised its full-year organic revenue growth guidance by 100 basis points, signaling confidence in the momentum.
IQVIA's Emerging Biopharma (EBP) segment, which now accounts for 70% of global clinical trial starts, is a key driver. The company noted that its revenue exposure to EBPs is 35%, higher than any other contract research organization (CRO) peer. New drug launches increased by 45% in the first half of 2026, reflecting a robust pipeline.
Large pharmaceutical companies are increasingly outsourcing full commercialization of therapies in select geographies, a trend IQVIA is capitalizing on to capture market share. Additionally, large pharma clients may double their study portfolios, leading to requests for IQVIA to add thousands of full-time employees (FTEs).
AI-enabled capabilities are helping IQVIA win complex Phase III awards by improving study design, site startup, and patient recruitment predictability. Four of the top 10 pharma companies have contracted to co-develop AI solutions with IQVIA. The company expects AI to contribute more directly to top-line growth as clients move from pilots to broad deployment of IQVIA AI agents.
Operational productivity programs drove 90 basis points of margin expansion. Adjusted EBITDA margin guidance for the remainder of 2026 is approximately 23.2%, flat year-over-year. The book-to-bill ratio was 1.22 in Q2 2026, indicating strong future revenue coverage.
In Q2 2026, IQVIA completed the acquisition of certain Charles River assets, adding 50 basis points to M&A revenue growth. Inactive trials represent approximately 5% of IQVIA's backlog, lower than some competitors, and the company requires signed contracts for all reported bookings. Potential future adjustments for inactive trials are being reviewed for Q3, with zero impact on historical results or next-12-month revenue.
Looking ahead, the outsourcing market is expected to expand through 2027, driven by AI in drug discovery increasing the volume of molecules entering development. AI in discovery is expected to boost demand for CRO services as more molecules with higher predictable success rates enter the pipeline. IQVIA is actively expanding capabilities in the development supply chain, including recent discovery asset acquisitions, and aims to leverage deep client relationships to provide integrated services from discovery through commercialization.